[1]雷秦,王娟.Bcl-2与Bcl-6在弥漫性大B细胞淋巴瘤中的表达及意义[J].现代检验医学杂志,2015,30(05):94-96.[doi:10.3969/j.issn.1671-7414.2015.05.028]
　LEI Qin,WANG Juan.Expression and Significance of Bcl-2 and Bcl-6 in Diffuse Large B-cell Lymphoma[J].Journal of Modern Laboratory Medicine,2015,30(05):94-96.[doi:10.3969/j.issn.1671-7414.2015.05.028]
点击复制

Bcl-2与Bcl-6在弥漫性大B细胞淋巴瘤中的表达及意义()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第30卷
期数:
2015年05期
页码:
94-96
栏目:
论著
出版日期:
2015-12-10

文章信息/Info

Title:
Expression and Significance of Bcl-2 and Bcl-6 in Diffuse Large B-cell Lymphoma
作者:
雷秦; 王娟
陕西省核工业二一五医院，陕西咸阳712000
Author(s):
LEI Qin; WANG Juan
Nuclear Industry 215 Hospital of Shaanxi Province，Shaanxi Xianyang 712000，China
关键词:
弥漫性大B细胞淋巴瘤; Bcl-2; Bcl-6; 预后
分类号:
R733.4；R730.43
DOI:
10.3969/j.issn.1671-7414.2015.05.028
文献标志码:
A
摘要:
目的探讨Bcl-2和Bcl-6在弥漫性大B细胞淋巴瘤(diffuse large B cell lymphoma，DLBCL)中的表达及意义。方法收集46例2004年1月～2014年6月经行淋巴结活检初诊的DLBCL病例及病理资料，采用免疫组化方法检测DLBCL患者组织中Bcl-2及Bcl-6的表达情况，分析二者免疫组化指标与DLBCL临床特征及预后的关系。结果①46例DLBCL中行Bcl-2检测，阳性表达率为63.04%(29/46例)，行Bcl-6检测，阳性表达率为73.91%(34/46例)。②Bcl-2和Bcl-6表达与患者性别、年龄、有无全身症状、有无结外侵犯及PS评分无关(P>0.05)，而与临床分期和IPI评分呈正相关(P<0.05)。③Bcl-2和Bcl-6表达阳性患者其近期疗效和预后(总体生存期和无进展生存期)显著低于阴性患者，组间差异有统计学意义(P<0.05)。结论Bcl-2和Bcl-6阳性表达提示近期疗效与预后不佳，其水平可被视为独立的DLBCL分析因素，对患者治疗过程中病情发展的预测、个体化治疗策略的制定有重要意义。
Abstract:
ObjectiveTo investigate the expression and significance of Bcl-2 and Bcl-6 in diffuse large B-cell lymphoma (diffuse large B cell lymphoma，DLBCL)．MethodsThe expressions of Bcl-2 and Bcl-6 of 46 inpatients，who first diagnosed DLBCL based on lymph node biopsy between January 2004 and June 2014，were detected by immunohistochemistry，and the data were analyzed about the relationship of clinical features and prognosis of the patients．Results①The Bcl-2 expression rate was 63.04% (29/46)，the Bcl-6 expression rate was 73.91% (34/46)．②There was no relationship between the expression of Bcl-2 and Bcl-6 and the following factors，including gender，age，systemic symptoms， invasion of extra nodal and PS score (P>0.05)，but there was positive correlation between the expression of Bcl-2 and Bcl-6 and clinical stage and IPI score (P<0.05)．③The recently efficacy and prognosis (overall survival and progression-free survival) of patients，who with the expression of Bcl-2 and Bcl-6，were significantly lower than the patients who without expression of Bcl-2 and Bcl-6 (P<0.05)．ConclusionThe recently efficacy and prognosis of patients are poor， who with the expression of Bcl-2 and Bcl-6，the expression level of Bcl-2 and Bcl-6 can be regarded as an independent prognostic factor of DLBCL．It has significance for prediction of disease development and individualized treatment of patients．

参考文献/References:

［1］Zhang J，Grubor V，Love CL，et al．Genetic heterogeneity of diffuse large B-cell lymphoma［J］．Proc Natl Acad Sci U S A，2013，110(4)：1398-1403．
[2]Chapuy B，McKeown MR，Lin CY，et al．Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma［J］．Cancer Cell，2013，24(6)：777-790．
[3]Uccini S，Al-Jadiry MF，Scarpino S，et al．Epstein-Barr virus-positive diffuse large B-cell lymphoma in children：a disease reminiscent of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly［J］．Hum Pathol，2015，46(5)：716-724．
[4]Tien YY，Link BK，Brooks JM，et al．Treatment of diffuse large B-cell lymphoma in the elderly：regimens without anthracyclines are common and not futile［J］．Leuk Lymphoma，2015，56(1)：65-71．
[5]Arora N，Manipadam MT，Pulimood A，et al．Gastrointestinal lymphomas：pattern of distribution and histological subtypes：10 years experience in a tertiary centre in South India［J］．Indian J Pathol Microbiol，2011，54(4)：712-719．
[6]Lerch K，Meyer AH，Stroux A，et al．Impact of prior treatment on outcome of transformed follicular lymphoma and relapsed de novo diffuse large B cell lymphoma：a retrospective multicentre analysis［J］．Ann Hematol，2015，94(6)：981-988．
[7]Maegawa S，Kuroda J，Kobayashi T，et al．Clinical ma-nifestation and prognostic factors of 32 Japanese patients with autoimmune disease-associated diffuse large B-cell lymphoma［J］．Leuk Lymphoma，2015，56(3)：785-788．
[8]Niitsu N，Hagiwara Y，Tanae K，et al．Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy［J］．J Clin Oncol，2010，28(34)：5097-5100．
[9]Ratajczak P，Leboeuf C，Wang L，et al．BCL2 expression in CD105 positive neoangiogenic cells and tumor progression in angioimmunoblastic T-cell lymphoma［J］．Mod Pathol，2012，25(6)：805-814．
[10]金华，刘继斌．弥漫性大B细胞淋巴瘤患者血清IL-6 水平的临床价值［J］．现代检验医学杂志，2012，27(6)：123-125． Jin H，Liu JB．Clinical significance of plasma interleukin-6 level in diffuse large B-cell lymphoma［J］．Journal of Modern Laboratory Medicine，2012，27(6)：123-125．

备注/Memo

备注/Memo:
作者简介：雷秦(1977-)，女，本科，主治医师，主要从事血液肿瘤研究，Tel：13892980177，E-mail：37833373@qq.com。
更新日期/Last Update: 1900-01-01